Aquinnah has developed a revolutionary approach to ALS and Alzheimer’s disease that has the potential to arrest, and possibly even reverse, these diseases. The company’s discovery of the connection between stress granules, aggregations of protein in the brain, and neurodegenerative disease has opened up exciting new avenues of treatment.
ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig’s disease, is a progressive fatal disease, caused by the loss of motor neurons in the brain and results in the eventual shut down of one’s ability to walk, talk and finally breathe. ALS progresses rapidly, killing over half the patients in only three years from the time of diagnosis. Alzheimer’s disease presents with a gradual loss of memory, the ability for complex reasoning and decision-making.
To take on these challenges, Aquinnah has assembled an elite team of award-winning scientists. The company’s advancements are built on the ground-breaking work of Co-founder Ben Wolozin, MD, PhD, recipient of the prestigious Zenith Fellows Award and former chairman of the National Institutes of Health Cellular and Molecular Biology Neurodegeneration Study Section. Other key team members include Glenn Larsen, co-founder, president and CEO, Bob Carpenter, and Duane Burnett, PhD.
In 2016, the London-based New Economy magazine named Aquinnah the Most Innovative Neurodegenerative Research Company.
- Glenn Larsen, PhD President and CEO
- Benjamin Wolozin, MD, PhD Chief Scientific Officer
- Duane Burnett, PhD VP of Medicinal Chemistry